Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Intra-Cellular Ther (ITCI)

Intra-Cellular Ther (ITCI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Intra-Cellular Ther 135 ROUTE 202/206 SUITE 6 BEDMINSTER NJ 07921 USA

www.intracellulartherapies.com Employees: 610 P: 646-440-9333 F: 646-440-9334

Description:

Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York.

Key Statistics

Overview:

Market Capitalization, $K 9,290,269
Enterprise Value, $K 9,140,749
Shares Outstanding, K 106,017
Annual Sales, $ 464,370 K
Annual Net Income, $ -139,670 K
Last Quarter Sales, $ 175,380 K
Last Quarter Net Income, $ -26,320 K
EBIT, $ -121,620 K
EBITDA, $ -129,490 K
60-Month Beta 0.97
% of Insider Shareholders 2.60%
% of Institutional Shareholders 92.33%
Float, K 103,261
% Float 97.40%
Short Volume Ratio 0.40

Growth:

1-Year Return 54.55%
3-Year Return 117.55%
5-Year Return 778.06%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 48.59%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.25 on 10/30/24
Next Earnings Date N/A
Earnings Per Share ttm -0.87
EPS Growth vs. Prev Qtr -56.25%
EPS Growth vs. Prev Year 0.00%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

ITCI Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -9.93%
Return-on-Assets % -8.38%
Profit Margin % -30.08%
Debt/Equity 0.00
Price/Sales 20.14
Price/Cash Flow N/A
Price/Book 8.19
Book Value/Share 10.80
Interest Coverage -0.66
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar